TABLE 1.
Characteristics of the included studies
| Study | Country | Period of enrollment | Sample size | POLEmut | MSI/MMRd | TP53mut/p53abn | NSMP | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Test | Positive (%) | Test | Positive (%) | test | positive (%) | positive (%) | ||||
| McConechy 2015 | Canada | Unclear | 30 | Mol | 1 (3.3) | IHC | 1 (3.3) | mol, IHC | 23 (76.7) | 5 (16.7) |
| Cherniak 2017 | USA | Unclear | 57 | Mol | 1 (1.8) | Mol | 2 (3.5) | mol | 50 (87.7) | 4 (7) |
| Jones 2019 | USA | 2007–2012 | 27 | Not assessed | Not assessed | IHC | 12 (44.4) | IHC | 11 (40.7) | 4 (14.8) |
| Gotoh 2019 | Japan | 1998–2015 | 92 | Mol | 10 (10.9) | Mol | 24 (26.1) | mol | 49 (53.3) | 9 (9.8) |
| Saijo 2019 | Japan | 2007–2017 | 57 | Not assessed | Not assessed | IHC | 6 (10.5) | IHC | 34 (59.6) | 17 (29.8) |
Abbreviations: IHC, immunohistochemistry; Mol, molecular analysis.